350 related articles for article (PubMed ID: 8608665)
1. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
Radermacher J; Koch KM
Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
[TBL] [Abstract][Full Text] [Related]
2. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
[TBL] [Abstract][Full Text] [Related]
3. Who should receive recombinant human erythropoietin?
Van Stone JC
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):3-7. PubMed ID: 2669084
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
Mohini R
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
[TBL] [Abstract][Full Text] [Related]
5. Management of blood pressure changes during recombinant human erythropoietin therapy.
Levin N
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
Phair JP; Abels RI; McNeill MV; Sullivan DJ
Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for recombinant human erythropoietin therapy.
Eschbach JW; Adamson JW
Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):2-8. PubMed ID: 2667349
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human erythropoietin for the treatment of anemia in patients with advanced cancer.
Henry DH
Semin Hematol; 1993 Oct; 30(4 Suppl 6):12-6. PubMed ID: 8153671
[TBL] [Abstract][Full Text] [Related]
9. Monitoring considerations in recombinant human erythropoietin therapy.
Ogden DA
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
[TBL] [Abstract][Full Text] [Related]
10. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO).
Roger SD; Baker LR; Raine AE
Clin Nephrol; 1993 Feb; 39(2):103-10. PubMed ID: 8448912
[TBL] [Abstract][Full Text] [Related]
11. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients.
Delano BG
Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):14-8. PubMed ID: 2757025
[TBL] [Abstract][Full Text] [Related]
12. Practical considerations of recombinant human erythropoietin therapy.
Paganini EP; Latham D; Abdulhadi M
Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):19-25. PubMed ID: 2667348
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of anemia in patients with renal failure using erythropoietin obtained by genetic recombination].
Wiecek A; Kokot F; Grzeszczak W; Klin M
Pol Tyg Lek; 1990 Sep 17-24; 45(38-39):782-6. PubMed ID: 2095546
[TBL] [Abstract][Full Text] [Related]
14. [Left ventricular hypertrophy in end-stage renal disease and its possible regression as a result of correction of anemia and arterial hypertension].
Dzgoeva FU; Gatagonova TM; Kadzaeva ZK; Khamitsaeva OV; Kochisova ZKh; Dzutseva AT; Bazaeva BG
Ter Arkh; 2011; 83(6):42-6. PubMed ID: 21786575
[TBL] [Abstract][Full Text] [Related]
15. Improved sexual function in hemodialysis patients on recombinant erythropoietin: a possible role for prolactin.
Schaefer RM; Kokot F; Wernze H; Geiger H; Heidland A
Clin Nephrol; 1989 Jan; 31(1):1-5. PubMed ID: 2914405
[TBL] [Abstract][Full Text] [Related]
16. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in normotensive and in untreated borderline hypertensive hemodialysis patients.
Lebel M; Kingma I; Grose JH; Langlois S
Am J Hypertens; 1995 Jun; 8(6):545-51. PubMed ID: 7662237
[TBL] [Abstract][Full Text] [Related]
17. Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (r-HuEPO).
Jeren-Struji'c B; Raos V; Jeren T; Horvatin-Godler S
Angiology; 2000 Feb; 51(2):131-9. PubMed ID: 10701721
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
[TBL] [Abstract][Full Text] [Related]
19. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
[TBL] [Abstract][Full Text] [Related]
20. [Initial response to treatment with erythropoietin in anemia caused by chronic renal insufficiency].
Sánchez Casajús A; Barrau J; Gómez Alamillo C; Jaurrieta F
Sangre (Barc); 1990 Feb; 35(1):82-4. PubMed ID: 2333585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
